Business
Lumexa Imaging Announces Fourth Quarter and Full Year 2025 Results, Reiterates Full Year 2026 Guidance
RALEIGH, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today
About this update from Lumexa Imaging Holdings, Inc.
[{"type":"text","content":"RALEIGH, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced certain financial results for the fourth quarter ended December 31, 2025, and reiterated full year 2026 guidance. The financial results included in this release pertaining to the fourth quarter and full year 2025 are preliminary, unaudited, and subject to final review and adjustment. “The fourth quarter of 2025 marked a strong close to an important year for Lumexa Imaging, with continued momentum across the business,” said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. “Strong Adjusted EBITDA growth was driven by advanced imaging volumes, ramping new de novo centers, and our return in-network with a large payer in New Jersey. We strengthened our balance sheet, reducing leverage by two turns, and opened a record number of de novo centers during the year, setting the stage for future growth.” Ms. Zulla continued, “Looking ahead, our 2026 outlook reflects continued growth and margin expansion, supported by durable demand tailwinds and the ongoing shift to outpatient care. With a focused strategy centered on same-center growth, geographic expansion, and advanced imaging, we believe Lumexa Imaging is well positioned to deliver sustained, profitable growth while expanding access to high-quality, lower-cost imaging for patients, providers, and payors.” Fourth Quarter 2025 Highlights:All comparisons are to the quarter ended December 31, 2024, unless otherwise noted Consolidated revenues of $267.7 million, an increase of 7.9% from $248.0 millionSystem-wide revenue growth of 10.6%Same center advanced volume growth: 12.7% for consolidated and 9.2% for system-wideNet loss of $28.7 million compared to $25.1 millionAdjusted EBITDA of $63.8 million, an increase of 18.6% from $53.7 million; and a 23.8% Adjusted EBITDA marginAchieved a two-turn reduction in leverage from 5.5 times to 3.5 times, resulting in more than $50 million in annual cash savings 2025 Full Year Highlights:All comparisons are to the year ended December 31, 2024, unless otherwise noted Added ten new imaging facilities: Nine de novo centers (six wholly owned and three through joint ventures) and one acquired siteConsolidated revenues of $1.023 billion, an increase of 7.8% from $948.9 millionSystem-wide...